Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.5MCash on Hand
5.6mo Cash Runway
Follow BYSI by emailGet an email when BYSI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BYSI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $2.1 million, up from $1.6 million, with cash and short-term investments of $0.6 million at September 30, 2026. FDA granted Fast Track designation to Plinabulin plus docetaxel for post-ICI non-squamous NSCLC without AGA. Subsidiary BeyondSpring Ltd. sold to Biolin on September 30, 2026. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Shareholder vote Shareholders met on October 13, 2026, with 20,905,921 ordinary shares present or represented, about 50.84% of the 41,119,820 outstanding. Shareholders ratified CBIZ CPAs P.C. as independent registered accounting firm for fiscal 2026, with 20,810,814 for, 65,954 against and 29,153 abstaining. Form 8-K · SEC filing
Oct 6, 2026 ·
Deal BeyondSpring sold all shares of BeyondSpring Ltd. to Biolin Investment Limited, closing September 30, 2026. The company received no cash, only a data license and a contingent clawback tied to China trial enrollment. Form 8-K · SEC filing · Press release
Oct 2, 2026 ·
Listing Nasdaq notified the company on September 29, 2026 that its market value of listed securities has been below $35 million for 30 consecutive business days, a continued listing deficiency. The company has until March 29, 2027 to regain compliance, and its shares continue to trade on Nasdaq meanwhile. Form 8-K · SEC filing
Sep 29, 2026 ·
Financing BeyondSpring filed to sell up to 9,200,000 ordinary shares through Citizens JMP at up to 3.0% commission, with aggregate offering capacity of up to $11,942,800 under baby-shelf limits. The 2019 ATM program was terminated effective September 9, 2026. Form 424B5 · SEC filing
Sep 29, 2026 ·
Deal BeyondSpring received FDA Fast Track designation for Plinabulin with docetaxel in post-immunotherapy non-squamous NSCLC. It also agreed to sell its majority-owned Chinese subsidiary to Biolin Investment, which will fund about 221 China patients in the Phase 3 DUBLIN-4 trial for no cash payment. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Listing Received a Nasdaq notice on September 17, 2026, that its ordinary shares have closed below $1.00 for 30 consecutive business days. The company has until March 16, 2027, to regain compliance, with a possible additional 180-day period. Shares continue to trade on Nasdaq for now. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2029 · Phase 3 · Upcoming Trial · Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BYSI's own candidates): Docetaxel Anhydrous, Pegfilgrastim, Ipilimumab, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BYSI holds $6.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations,
an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 0 months +40
ATM program on file since Sep 2026 +15
Shelf registration (F-3, Jun 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.10-Q, Nov 2026
Share count 41,409,059 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BYSI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BYSI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.